SCHEMBL17144192

SCHEMBL17144192

CCN(CC)C(=O)CCN(CC(N)=O)C(C)c1cc(C(=O)O)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5B Q9UGL1 15/20 0.42
▸ KDM5A P29375 11/20 0.41
▸ KDM5C P41229 6/20 0.41
▸ KDM4A O75164 4/20 0.41
▸ KDM6B O15054 2/20 0.41
▸ KDM2B Q8NHM5 1/20 0.41
▸ KDM4C Q9H3R0 5/20 0.36
▸ KDM5D Q9BY66 1/20 0.36
▸ GABRP O00591 1/20 0.35
▸ GABRD O14764 1/20 0.35
▸ GABRA1 P14867 1/20 0.35
▸ GABRB1 P18505 1/20 0.35
▸ GABRG2 P18507 1/20 0.35
▸ GABRB3 P28472 1/20 0.35
▸ GABRA5 P31644 1/20 0.35
▸ GABRA3 P34903 1/20 0.35
▸ GABRA2 P47869 1/20 0.35
▸ GABRB2 P47870 1/20 0.35
▸ GABRA4 P48169 1/20 0.35
▸ GABRE P78334 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19741728 0.72 KDM5B (0.42) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL17144478 0.70 KDM5B (0.55) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL17545205 0.67 GABRP (0.56) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL19705976 0.67 KDM4C (0.46) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL17144634 0.67 KDM5B (0.51) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL25933767 0.67 KDM5B (0.49) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL1759894 0.66 KDM4C (0.55) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL16054683 0.65 KDM4C (0.50) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL25933765 0.65 KDM4C (0.53) KDM5BKDM5AKDM5CKDM4AKDM6B
SCHEMBL5358458 0.65 KDM4C (0.46) KDM5BKDM5AKDM5CKDM4AKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US claimed
EP-3126345-A1 INHIBITORS OF HISTONE DEMETHYLASES Gilead Sciences, Inc. (US) 2017-02-08 — — EP claimed
WO-2015153498-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS, APS (DK) 2015-10-08 — — WO claimed
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US disclosed
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES KDM1B, KDM3A, KDM1A KDM5B 33/4885KDM5A 23/4885KDM5C 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback